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initiation and progression in experimental cardiomyocyte 
and dog models for AF. However, it is still unclear whether 
induction of HSPs also prolongs the arrhythmia-free inter-
val after, for example, cardioversion of AF.
In this review, we discuss the role of HSPs in the pathophys-
iology of AF and give an outline of the HALT&REVERSE 
project, initiated by the HALT&REVERSE Consortium 
and the AF Innovation Platform. This project will elucidate 
whether HSPs (1) reverse cardiomyocyte electropathology 
and thereby halt AF initiation and progression and (2) rep-
resent novel biomarkers that predict the outcome of AF 
conversion and/or occurrence of post-surgery AF.
Keywords Atrial fibrillation · Mapping · 
Electropathology · Heat shock proteins · 
Geranylgeranylacetone
Introduction
Atrial fibrillation (AF) represents the arrhythmia with the 
highest prevalence, accounting for one-third of hospitalisa-
tions related to cardiac rhythm disturbances [1]. The main 
risk factors to develop AF include age, cardiac surgery, val-
vular heart disease, congestive heart disease, ischaemic car-
diomyopathy, obesity, hypertension and diabetes mellitus. 
These risk factors cause atrial stretch and dilation and con-
dition the heart for AF [1]. Patients with AF are frequently 
encountered in daily clinical practice. The goal of therapy 
in AF is, ideally, to abolish AF episodes and to restore 
sinus rhythm. This in turn re-establishes atrioventricular 
synchrony and improves atrial function. Despite extensive 
research, treatment of AF remains difficult, which is rooted 
in the persistent and progressive nature of this arrhythmia. 
An initiator, trigger and substrate are mandatory for devel-
Abstract Atrial fibrillation (AF) is the most common age-
related cardiac arrhythmia accounting for one-third of hos-
pitalisations. Treatment of AF is difficult, which is rooted 
in the progressive nature of electrical and structural remod-
elling, called electropathology, which makes the atria more 
vulnerable for AF. Importantly, structural damage of the 
myocardium is already present when AF is diagnosed for 
the first time. Currently, no effective therapy is known that 
can resolve this damage.
Previously, we observed that exhaustion of cardiopro-
tective heat shock proteins (HSPs) contributes to structural 
damage in AF patients. Also, boosting of HSPs, by the heat 
shock factor-1 activator geranylgeranylacetone, halted AF 
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opment of AF. In this manuscript, we will focus on the sub-
strate underlying AF.
AF persistence is caused by progressive changes in the 
electrophysiology and structure of atrial cardiomyocytes [2], 
as demonstrated in a goat model for AF. In this model, AF 
resulted in shortening of the atrial effective refractory period 
and reversion of the physiological rate adaptation (short-
ening of the atrial refractory period at slower heart rates), 
facilitating induction and stability of AF. Similar findings 
have been reported in humans. The goat model of AF also 
revealed that longstanding AF is associated with changes in 
myocardial structure, including dedifferentiation, increase 
in cell size, perinuclear accumulation of glycogen, central 
loss of sarcomeres, changes in mitochondrial shape, frag-
mentation of the sarcoplasmatic reticulum and disorganisa-
tion of fibre orientation [3]. These structural changes were 
observed in human AF as well [4]. Importantly, structural 
changes are sustainable and impair electrical coupling and 
the functional recovery to sinus rhythm by pharmacological 
and electrical cardioversion. In addition, it was found that 
alterations of the myocardial structure underlie changes in 
electrophysiology as observed in AF [2, 5]. This phenom-
enon is commonly defined as electropathology. It should 
be noted that electropathology is already present when a 
patient enters the clinic for the first time with an episode 
of AF. The currently available pharmacological therapy is 
directed at alleviation of electrical changes (rhythm control) 
and has limited effect on patient outcome [1]. Therapeutic 
approaches that halt the mechanisms conveying the AF-
induced structural remodelling may offer superior therapeu-
tic perspectives. Thus, from science to patients: reversal of 
electropathology of cardiomyocytes represents a key target 
to accomplish and maintain cardiac sinus rhythm after AF.
Discontinuous propagation in the atria
It is generally assumed that transition of short-lasting parox-
ysms of AF to long-lasting episodes that no longer terminate 
spontaneously over time corresponds to a progression from 
a trigger-driven to a substrate-mediated arrhythmia due to 
a combination of electrical, structural and contractile atrial 
remodelling (Fig. 1). Previous studies have demonstrated 
that alterations in the atrial microscopic structure impair 
intra-atrial conduction [6]. Spach et al. [7, 8] were the first to 
provide evidence that two-dimensional propagation is dis-
continuous in nature at a microscopic level (Fig. 2). In their 
experiments, variations in shape and amplitude of extracel-
lular potential waveforms were studied when the direction 
of conduction was changed from longitudinal to transverse 
in relation to the fibre axis. They observed that in uniform 
anisotropic myocardium, the shape of the upstroke of the 
transmembrane action potential depended on the direction 
of propagation in relation to the fibre orientation. Fast con-
duction in the longitudinal direction was associated with a 
slow upstroke and a long τ-foot (time constant of the action 
potential representing voltage decay) and slow conduction 
in the transverse direction with a fast upstroke and a short 
τ-foot. Differences were explained by the anisotropic distri-
bution of intercellular connections (gap junctions, connex-
ions). This was confirmed in a goat model for sustained (2 
months) AF, where persistence of AF was associated with a 
lower density and inhomogeneous distribution of gap junc-
tions [9, 10]. Gap junctions along the fibre axis provide a 
low resistance to current flow that increases the space con-
stant and hence the electrotonic current flow. Subsequently, 
the upstroke of the transmembrane potential in this direction 
decreases and the τ-foot increases. Due to the high resis-
tance barriers in the transverse direction, the space constant 
is reduced and the electrotonic current is therefore smaller. 
This results in an increase in the upstroke of the transmem-
brane potential and a decrease in the τ-foot. Consequently, 
as the safety factor is lower during longitudinal conduc-
tion than during transverse conduction, conduction block is 
more likely to occur during longitudinal conduction [11].
Next to gap junctional remodelling, also ion channel 
remodelling has been demonstrated to play a role in AF pro-
gression. A marked reduction in ion (preferably L-type Ca2+ 
and transient outward K+) channel protein expression, asso-
ciated with a shortening of atrial effective refractory period, 
Fig. 1 Persistence of atrial fibrillation. Surface electrograms of par-
oxysms (upper panel) and persistent (lower panel) atrial fibrillation. 
Wave-maps constructed during these different types of maps are also 
shown. A wave-map shows individual fibrillation waves represented 
by colours according to their sequence of appearance. A previously 
described mapping algorithm was used to classify them into peripheral 
waves (entering the mapping area from outside the electrode array), 
breakthrough waves (appearing at the epicardial surface inside the 
mapping area) or discontinuous conduction waves (fibrillation waves 
starting with a delay of 13–40 ms from boundaries of other waves). 
Sites of epicardial breakthroughs are indicated by white asterisks; 
white arrows indicate direction(s) of expansion of epicardial break-
through or discontinuous fibrillation waves. Peripheral fibrillation 
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anisotropy (structural, as explained above). During AF, mul-
tiple, simultaneously circulating wavelets excite the atria. A 
fibrillation wave may encounter atrial tissue that is partially 
or totally refractory due to previous excitation by another 
wave. This results in slowing of conduction, conduction 
block and turning of fibrillation waves around lines of con-
duction block. All these conduction abnormalities give rise 
to local asynchronous activation of the myocardium and 
thus to multiple deflections in the extracellular potentials.
High-density epicardial mapping during electrically 
induced AF in humans without structural heart disease 
showed that there is a relation between the degree of frac-
tionation in the right atrium and specific spatial patterns of 
activation. Double potentials were recorded along the lines 
of conduction block (Fig. 3), whereas electrograms with 
three or more deflections were recorded at pivot points or 
areas of slow conduction [15, 16]. In older patients with 
structural heart disease and longstanding persistent AF, it is 
likely that fractionation is more structurally determined due 
to dissociation of muscle bundles by fibrosis or fatty degen-
eration. Recent studies suggested that ablation of areas with 
fractionated electrograms may eliminate AF suggesting that 
fractionated electrograms are indeed indicative for arrhyth-
mogenic regions perpetuating AF [17].
was observed in patients with AF [12]. This decrease in pro-
tein expression might be explained by increased (calcium 
dependent) calpain I activity, causing enhanced degradation 
of ion-channel proteins and contractile proteins in the myo-
cardium [4, 13].
Modifications of the atrial architecture affecting cardio-
myocyte geometry (size and shape), gap junctions (distri-
bution and conductivity) or the interstitial space (size and 
distribution) result in non-uniform anisotropic tissue. Mus-
cle bundles become electrically dissociated due to strands 
of fibrotic tissue giving rise to fractionation of extracellular 
potentials [14]. These areas of local conduction abnormali-
ties may facilitate genesis and perpetuation of AF.
Fractionation of extracellular potentials
Fractionated electrograms are extracellular waveforms 
containing multiple, distinct deflections reflecting local 
asynchronous activation of myocardium surrounding the 
recording electrode [14]. Fractionation of fibrillation poten-
tials can be functional and/or structural in nature as local 
asynchronous activation can be the result of a spatial disper-
sion in refractory periods (functional) or non-uniform tissue 
Fig. 2 Discontinuous conduction. a Electrograms recorded in the 
longitudinal and transversal conduction direction in relation to fibre 
orientation in uniform anisotropic and non-uniform anisotropic tissue. 
The electrogram in the transverse conduction direction in non-uniform 
anisotropic tissue consists of multiple deflections indicating discon-
tinuous conduction. These alterations may be caused by changes in 
myocardial structure, including increase in cell size, perinuclear accu-
mulation of glycogen, central loss of sarcomeres (myolysis), changes 
in mitochondrial shape, fragmentation of the sarcoplasmatic reticulum 
and disorganisation of fibre orientation as (partly) observed in panel 
b and c. b Atrial myocardium from a patient in sinus rhythm (SR) 
and (c) a patient with permanent AF (PeAF) stained with toluidine 
blue. SR patients show normal structural cardiomyocytes, whereas the 
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of five HSP families, including the HSP70 and HSP27 fam-
ily, which have both been suggested to convey cardioprotec-
tive effects [19]. Therefore, impairment of HSP expression, 
especially HSP70 and HSP27, has been related to the devel-
opment of various cardiac diseases, including AF [20], but 
also metabolic diseases, such as diabetes and obesity [21], 
which trigger the induction of AF [1].
These findings indicate that HSPs represent an inter-
esting target to treat cardiac diseases such as AF. Indeed, 
experimental and human studies revealed that HSPs provide 
protection against AF initiation. In dogs, pretreatment with 
the HSP inducer, geranylgeranylacetone (GGA), attenu-
ates changes in electrophysiology and conduction veloc-
ity of atrial cardiomyocytes and prevents initiation of AF 
in (acute) ischaemia [22]. Also protective effects of HSPs 
were observed in a rabbit model for AF induced by heart 
failure [23]. A further indication for the protective effect 
of HSPs is obtained from two studies in patients undergo-
ing cardiac surgery. In both studies an inverse correlation 
between higher levels of HSP70 expression in atrial tissue 
and lower incidence of post-operative AF was observed [24, 
25]. In addition, one study described a correlation between 
HSP70 and HSP27 levels in tissue and improved restoration 
of sinus rhythm after mitral valve surgery [26]. In addition, 
high HSP27 levels in blood predict sinus rhythm mainte-
nance after catheter ablation in patients with paroxysmal AF 
[26]. In an experimental study in mice, it was observed that 
induction of HSP70 prevents angiotensin II-induced AF and 
limits atrial fibrosis formation [27]. Together, these results 
indicate that induction of HSPs mitigates the development 
of the atrial substrate for the induction of AF.
In addition to the cardioprotective effect of HSPs against 
the induction of AF, it is expected that induced expression 
of HSPs also protects against AF progression. Such a car-
dioprotective effect is supported by several studies. For 
example, general HSP levels were induced by a heat shock 
or GGA treatment in tachypaced HL-1 atrial cardiomyoyc-
tes and these cardiomyocytes were compared with normal 
tachypaced HL-1 cardiomyocytes [20, 28]. In these stud-
ies, tachypaced cardiomyocytes with induced HSP expres-
sion revealed improved contractile function and structural 
integrity. Similar protection by general HSP induction was 
obtained in a dog model for AF [28]. Dogs pretreated with 
GGA showed attenuation of tachypacing-induced AF pro-
motion and limited recurrence of AF after cardioversion, 
most likely by limiting the electrophysiological changes, 
including shortening of action potential duration and main-
tenance of L-type Ca2+ current [28]. Further studies revealed 
that specific members of the family of small HSPs play a 
key role in cardioprotection against AF. Induction of HSP27 
was found sufficient to prevent tachypacing-induced struc-
tural remodelling, while overexpressing HSP70 was not 
protective [28]. Other specific small HSP family members 
Counteracting electropathology by heat shock proteins
Previous research has unequivocally demonstrated that the 
induction of the heat shock response provides protection 
against various cardiac diseases [18]. Sensing of cellular 
stress activates the heat shock transcription factor-1 (HSF-
1) and consequently results in the expression of heat shock 
proteins (HSPs). In general, HSPs function as intra-cellular 
chaperones for other proteins. They play an important role 
in protein–protein interactions such as folding and assisting 
in the establishment of proper protein conformation (shape) 
and prevention of unwanted protein aggregation, which 
occur during ageing of the cell and (cardiac) stress [18]. 
Because of their essential role in protein maintenance, some 
members of the HSP family are expressed at low to moder-
ate levels in all organisms. In cardiomyocytes, HSPs bind 
to damaged proteins, including sarcomeric proteins, and 
thereby prevent cardiomyocyte toxicity and further struc-
tural remodelling and functional loss [19, 20]. HSPs consist 
Fig. 3 Double potentials recorded along the lines of conduction block. 
The colour-coded activation map (interelectrode distance, 2 mm) 
shows two fibrillation waves (its trajectories indicated by thick black 
lines) separated by areas of conduction block. Electrograms consist-
ing of two deflections are shown outside the activation map. They are 





Neth Heart J (2015) 23:327–333
sion is GGA. GGA was originally used as an anti-ulcer 
agent and is a non-toxic acyclic isoprenoid compound with 
a retinoid skeleton that induces HSP synthesis in various tis-
sues, including gastric mucosa, intestine, liver, heart, retina 
and the central nervous system [33, 34]. GGA induces HSP 
expression through the activation of HSF-1. The protective 
effect of GGA-induced HSP expression on electropathology 
caused by tachycardia has been observed in various experi-
mental models, including the dog model for AF [28]. These 
findings suggest that the induction of HSPs by GGA might 
have a potential value for clinical AF. In in vivo tachypaced 
Drosophila, GGA treatment protected against contractile 
dysfunction of the heart wall and structural remodelling 
[30]. Also in the dog model for (acute) atrial ischaemia and 
tachypacing-induced AF promotion, an HSP-inducing GGA 
treatment revealed protective effects against cardiomyocyte 
remodelling, and consequently occurrence and recurrence 
of AF [22]. A direct protective effect of HSP on the earlier-
mentioned gap junctional and ion channel remodelling has 
not been described (yet). However, it has been shown that 
GGA treatment attenuates the proteolytic activity of calpain 
[30] and prevents ion channel remodelling in AF [28], sug-
gesting a direct protective role of HSPs.
Although protective effects with GGA were observed, 
an important disadvantage of GGA is its high LogP value, 
which is around 9, and therefore generally high dosages are 
required, as found in the dog studies for AF [22, 28]. To 
overcome this disadvantage, various derivatives of GGA 
have been synthesised, with improved pharmaco-chemical 
and HSP-boosting properties (Fig. 4a). Some of these deriv-
atives also showed cardioprotective effects in tachypaced 
HL-1 cardiomyocytes (Fig. 4b). In the HALT&REVERSE 
project, we will test whether these derivatives reveal 
improved cardioprotective effects compared with GGA 
and elucidate their mode of action. In addition, one of the 
selected GGA derivatives will be further tested in an animal 
model for AF. Finally, GGA has also been tested in patients 
undergoing cardiac surgery, and atrial tissue will be used to 
test whether GGA induces HSP expression in patients and 
protects against post-surgery AF.
Expected findings of HALT&REVERSE
Ultimately, by inducing cardioprotective HSP expression, 
the HALT&REVERSE Consortium wants to halt or even 
reverse the structure of cardiomyocytes and therefore the 
electropathology in patients with AF (Fig. 4c). Hereby, 
we expect to significantly contribute to novel rational 
approaches, to enhance successful recovery of heart func-
tion after electrical cardioversion (ECV) and/or cardiac 
surgery. This approach will affect the substrate underlying 
AF, not the trigger. For the first time, we exploit HSP lev-
also show protection in cellular models, including HSP20, 
cvHSP and HSP22, but not the other small HSP family 
members [29]. Importantly, selective knockdown of HSP27 
fully attenuates the protective effect of GGA, demonstrat-
ing a main role for HSP27 in cardioprotection. A similar 
protective effect of the small HSP members as observed 
in HL-1 cardiomyocytes has been found in the Drosophila 
melanogaster (fruit fly) model for tachypacing-induced 
contractile dysfunction. In the transparent fruit fly pupae, 
the heart wall can be visualised and subjected to tachypac-
ing [30]. This model also allows for general induction of 
HSPs, either by heat shock or by HSP-inducing compounds 
such as GGA, or specific induction of HSPs via genetic 
manipulation specifically in the heart. Indeed, induction of 
HSPs, especially the small HSP, by these strategies prevents 
tachypacing-induced contractile dysfunction and structural 
remodelling in Drosophila pupae [30]. Also in human AF, 
there are indications that HSP27 may protect against cardiac 
remodelling and AF progression. Two independent studies 
report higher atrial expression levels of HSP27 to relate to a 
shorter duration of AF and less extensive structural damage 
[20, 31]. This suggests that in short-duration AF, the HSP 
response gets activated, while it diminishes over time when 
AF persists. As HSP27 conserves the cardiomyocyte struc-
ture, lower levels of HSP27 may trigger the progression of 
structural remodelling paving the way to longstanding and 
permanent AF. Therefore, securing HSP levels at an ade-
quate level, for example, by treatment with HSP inducers, 
may limit the expansion of the AF substrate during paroxys-
mal and short-term AF. In agreement with this hypothesis, 
restoration of sinus rhythm in patients with permanent AF 
after mitral valve surgery is related to the heat shock factor 
(HSF) -1 activity and induced HSP27 levels [32].
Taken together, induction of HSPs attenuates electro-
pathology of cardiomyocytes in AF. In Hsf1 Activators 
Lower cardiomyocyte damage: Towards a novel thera-
peutic approach to REVERSE atrial fibrillation (HALT & 
REVERSE), we will focus on the electropathological sub-
strate of AF and dissect the mechanism of protection.
Novel HSP-inducing agents as a therapeutic approach 
in AF
Pharmacological approaches to prevent mechanisms under-
lying atrial electropathology are being studied, with the hope 
that they might be useful therapeutic agents in treating AF 
[1]. It has been recognised that the efficacy of commonly 
used drugs on remodelling is limited [1]. As the protective 
action of HSPs depends on their temporary induction, drugs 
that boost the endogenous heat shock responses are of par-
ticular interest in the prevention of first onset, recurrence and 
progression of AF. A drug often used to boost HSP expres-
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source are credited.
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